Vaxart, Inc. - Common Stock (VXRT)
0.5041
+0.1112 (28.30%)
NASDAQ · Last Trade: Jun 11th, 11:36 PM EDT
Detailed Quote
Previous Close | 0.3929 |
---|---|
Open | 0.5997 |
Bid | 0.4700 |
Ask | 0.4800 |
Day's Range | 0.4910 - 0.6213 |
52 Week Range | 0.2850 - 1.070 |
Volume | 94,620,862 |
Market Cap | 76.61M |
PE Ratio (TTM) | -2.965 |
EPS (TTM) | -0.2 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 6,673,114 |
Chart
About Vaxart, Inc. - Common Stock (VXRT)
Vaxart Inc is a biotechnology company focused on developing oral vaccines based on its proprietary platform technology. The company aims to create innovative vaccines that are not only effective but also easy to administer, eliminating the need for needles. Vaxart's research and development primarily targets infectious diseases, with a particular emphasis on creating solutions for viral infections and other public health challenges. Through its unique oral delivery system, Vaxart strives to enhance patient compliance and broaden access to vaccination, ultimately contributing to global health improvement. Read More
News & Press Releases
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · June 11, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Via Chartmill · June 11, 2025
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Via Chartmill · June 11, 2025
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Via Chartmill · June 11, 2025
Via Benzinga · June 11, 2025
Via Benzinga · June 11, 2025
Via Benzinga · June 11, 2025

Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · February 24, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · February 24, 2025

The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill · February 24, 2025

Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a bullish outlook on its oral vaccines for COVID-19 and norovirus.
Via Benzinga · August 15, 2024

VXRT stock results show that Vaxart missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024

Via Benzinga · June 21, 2024

Via Benzinga · June 19, 2024

Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project NextGen award are expected to extend the company's cash runway into 2026.
Via Benzinga · June 17, 2024

Vaxart (VXRT) shares surged 23% in premarket session after receiving a $453 million project award from BARDA to conduct a COVID-19 vaccine study.
Via Benzinga · June 14, 2024

Via Benzinga · June 14, 2024

Pre-market stock movers are worth checking out on Friday as we dive into all of the biggest news moving shares this morning!
Via InvestorPlace · June 14, 2024

Via Benzinga · June 13, 2024